Research and experimental development on natural sciences and engineering
XELLIA PHARMACEUTICALS AS
Revenue 2024
NOK 83.1m
Operating profit
NOK 7.3m
Equity
NOK 707.2m
Incorporated
1994
Employees
30
Share capital
NOK 223.3m
Key figures · 2024
Current ratio
3.68
Equity ratio
90.5%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 8.8% | |
| Net margin (%%) | 89.5% | |
| Return on assets (%%) | 0.9% | |
| Likviditet | ||
| Current ratio | 3.68 | |
| Working capital | 190.7m | |
| Soliditet | ||
| Equity ratio (%%) | 90.5% | |
| Debt-to-equity ratio | 0.10 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.